Valbiotis Yönetim

Yönetim kriter kontrolleri 4/4

Valbiotis CEO'su Sebastien Peltier, Mar2017 tarihinde atandı, in görev süresi 7.67 yıldır. in toplam yıllık tazminatı € 301.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 59.8% maaş ve 40.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4% ine doğrudan sahiptir ve bu hisseler € 778.57K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 7.1 yıldır.

Anahtar bilgiler

Sebastien Peltier

İcra Kurulu Başkanı

€301.0k

Toplam tazminat

CEO maaş yüzdesi	59.8%
CEO görev süresi	7.7yrs
CEO sahipliği	4.0%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	7.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Sebastien Peltier'un ücretlendirmesi Valbiotis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€8m
Dec 31 2023	€301k	€180k	-€7m
Sep 30 2023	n/a	n/a	-€8m
Jun 30 2023	n/a	n/a	-€9m
Mar 31 2023	n/a	n/a	-€11m
Dec 31 2022	€318k	€180k	-€12m
Sep 30 2022	n/a	n/a	-€11m
Jun 30 2022	n/a	n/a	-€10m
Mar 31 2022	n/a	n/a	-€9m
Dec 31 2021	€259k	€180k	-€9m

Tazminat ve Piyasa: Sebastien 'nin toplam tazminatı ($USD 313.44K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 474.67K ).

Tazminat ve Kazançlar: Sebastien 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sebastien Peltier (46 yo)

7.7yrs

Görev süresi

€301,000

Tazminat

Mr. Sebastien Peltier, Ph D., HDR serves as the Chief Executive Officer of Valbiotis SA and is Co-Founder of Valbiotis. Mr. Peltier has been Member of Management Board of Valbiotis SA from March 7, 2017 an...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sebastien Peltier	Co-Founder	7.7yrs	€301.00k	4% € 778.6k
Sebastien Bessy	COO & Member of the Management Board	3.4yrs	€295.00k	0.035% € 6.8k
Pascal Sirvent	CSO & Member of the Management Board	6.2yrs	€236.00k	0.12% € 23.7k
Murielle Cazaubiel	CMO & Member of the Management Board	5.8yrs	€255.00k	0.0026% € 505.7
Stanislas Sordet	CFO & Member of Management Board	less than a year	Veri yok	Veri yok
Charlotte Jezequel	Director of HR & Member of Management Board	1.8yrs	Veri yok	Veri yok
Josep Infesta	Head of Global Business Development	5.8yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 8JD 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Agnes Tixier	Member of Supervisory Board	5.7yrs	Veri yok	Veri yok
Laurent Levy	Chairman of Supervisory Board	7.7yrs	Veri yok	Veri yok
Nathalie Boisseau	Member of Scientific & Medical Board	no data	Veri yok	Veri yok
Jean-Marie Bard	Member of Scientific & Medical Board	no data	Veri yok	Veri yok
Samy Hadjadj	Member of Scientific & Medical Board	no data	Veri yok	Veri yok
Thierry Maugard	Member of Scientific & Medical Board	no data	Veri yok	Veri yok
Bruno Guigas	Member of Scientific & Medical Board	no data	Veri yok	Veri yok
André Marette	Member of Scientific & Medical Board	no data	Veri yok	Veri yok
Jean Zetlaoui	Member of Supervisory Board	7.1yrs	Veri yok	Veri yok

7.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 8JD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).

Valbiotis Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

No independent directors

Valbiotis Announces Board of Directors Changes

Recent updates

New minor risk - Profitability

New major risk - Share price stability

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

New minor risk - Profitability

Valbiotis SA has filed a Follow-on Equity Offering in the amount of €15.000001 million.

Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure

Forecast breakeven date pushed back to 2024

Valbiotis SA announced that it has received €9.7 million in funding

Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

First half 2022 earnings released

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science

Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor

No independent directors

Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Full year 2021 earnings: Revenues miss analyst expectations

Valbiotis Announces Board of Directors Changes

Valbiotis SA to Report Fiscal Year 2021 Results on Mar 15, 2022

Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure

Forecast to breakeven in 2023

Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents its Comprehensive Clinical Development Plan

First half 2021 earnings released

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Full year 2020 earnings released

Valbiotis SA to Report First Half, 2021 Results on Sep 30, 2021

Valbiotis Selected to Present TOTUM-854 Results on Arterial Hypertension

Valbiotis SA Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Valbiotis Authorizes to Launch Heart, the Phase II Multi-Center Clinical Study with TOTUM-070, for the Reduction of Blood LDL-Cholesterol Levels

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi